Mathias Vrolix
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mathias Vrolix has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Jo Dens
Department of Cardiology, Hospital Oost-Limburg, Genk, Belgium
3 shared publications - Adel Aminian
Department of Cardiology, Centre Hospitalier Universitaire de Charleroi, Belgium (A.A.).
2 shared publications - Giovanni Amoroso
Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
2 shared publications - Luc Janssens
Imelda Ziekenhuis Bonheiden Belgium
2 shared publications - Peter Sinnaeve
Department of Cardiovascular Medicine, University Hospitals Leuven, Leuven, Belgium (P.S.).
2 shared publications - William Wijns
The Lambe Institute for Translational Medicine and CÚRAM, University of Galway, Galway, Ireland
2 shared publications
Latest Publications
- 14 July 2026
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 81 (9) , 1026-1036
Reducing cardiovascular risk in Belgium through practical and measurable initiatives: a multidisciplinary expert-led call to action
Cardiovascular diseases (CVDs) are the leading cause of death globally, accounting for an estimated 17.9 million deaths each year [1]. In Belgium alone, a country with a population of 11.7 million ...
- 14 July 2026
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 81 (9) , 1026-1036
Reducing cardiovascular risk in Belgium through practical and measurable initiatives: a multidisciplinary expert-led call to action
Cardiovascular diseases (CVDs) are the leading cause of death globally, accounting for an estimated 17.9 million deaths each year [1]. In Belgium alone, a country with a population of 11.7 million ...
- 1 February 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 18 (2) , e013584
Three-Dimensional CT for Preprocedural Planning of PCI for Ostial Right Coronary Artery Lesions: A Randomized Controlled Pilot Trial
BACKGROUND: Geographic stent-ostium mismatch is an important predictor of target lesion failure after percutaneous coronary intervention of an aorto-ostial right coronary artery lesion. Optimal visualization of the aorto-ostial plane is crucial for precise stent implantation at the level of the ostium. This study investigates whether preprocedural 3-dimensional computed tomography (3DCT), with determination of the optimal viewing angle, would allow for more precise stent implantation and reduce procedure time, contrast, and radiation dose. METHODS: In this single-center, prospective, open-label, core-laboratory blinded trial, a total of 30 patients with an aorto-ostial right coronary artery lesion were randomly assigned to either percutaneous coronary intervention with a preprocedural 3DCT or angiography-guided percutaneous coronary intervention. The optimal working view angle was determined by 3DCT in the intervention group and by the operators’ discretion in the control group. The primary end point was the percentage of patients without geographic mismatch, as determined by intravascular ultrasound. RESULTS: 3DCT-determined C-arm angles were heterogenous but, in general, more extreme left anterior oblique projections were used ( P P =0.06). The mean amount of procedural contrast ( P P =0.03), and median procedure time ( P =0.03) were significantly lower in the intervention group. The 3DCT scan was able to predict the calcium arc ( P P =0.003). CONCLUSIONS: Preprocedural 3DCT planning for percutaneous coronary intervention of aorto-ostial right coronary artery lesions allows for optimal stent positioning while reducing procedure time, contrast, and radiation dose. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05172323.
- 1 February 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 18 (2) , e013584
Three-Dimensional CT for Preprocedural Planning of PCI for Ostial Right Coronary Artery Lesions: A Randomized Controlled Pilot Trial
BACKGROUND: Geographic stent-ostium mismatch is an important predictor of target lesion failure after percutaneous coronary intervention of an aorto-ostial right coronary artery lesion. Optimal visualization of the aorto-ostial plane is crucial for precise stent implantation at the level of the ostium. This study investigates whether preprocedural 3-dimensional computed tomography (3DCT), with determination of the optimal viewing angle, would allow for more precise stent implantation and reduce procedure time, contrast, and radiation dose. METHODS: In this single-center, prospective, open-label, core-laboratory blinded trial, a total of 30 patients with an aorto-ostial right coronary artery lesion were randomly assigned to either percutaneous coronary intervention with a preprocedural 3DCT or angiography-guided percutaneous coronary intervention. The optimal working view angle was determined by 3DCT in the intervention group and by the operators’ discretion in the control group. The primary end point was the percentage of patients without geographic mismatch, as determined by intravascular ultrasound. RESULTS: 3DCT-determined C-arm angles were heterogenous but, in general, more extreme left anterior oblique projections were used ( P P =0.06). The mean amount of procedural contrast ( P P =0.03), and median procedure time ( P =0.03) were significantly lower in the intervention group. The 3DCT scan was able to predict the calcium arc ( P P =0.003). CONCLUSIONS: Preprocedural 3DCT planning for percutaneous coronary intervention of aorto-ostial right coronary artery lesions allows for optimal stent positioning while reducing procedure time, contrast, and radiation dose. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05172323.
- 5 July 2021
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 77 (4) , 322-327
FFR pressure wire comparative study: piezoresistive versus optical sensor
This study aimed to assess the reliability of pressure derived fractional flow reserve (FFR) measurement and the handling performance of the OptoWire Deux with an optical pressure sensor relative t...
- 5 July 2021
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 77 (4) , 322-327
FFR pressure wire comparative study: piezoresistive versus optical sensor
This study aimed to assess the reliability of pressure derived fractional flow reserve (FFR) measurement and the handling performance of the OptoWire Deux with an optical pressure sensor relative t...
- 1 February 2021
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 14 (2) , 144-151
Comparison of Investigator-Reported and Clinical Event Committee–Adjudicated Outcome Events in GLASSY
Background: Event adjudication by a clinical event committee (CEC) provides a standardized, independent outcome assessment. However, the added value of CEC to investigators reporting remains debated. GLASSY (GLOBAL LEADERS Adjudication Sub-Study) implemented, in a subset of the open-label, investigator-reported (IR) GLOBAL LEADERS trial, an independent adjudication process of reported and unreported potential outcome events (triggers). We describe metrics of GLASSY feasibility and efficiency, diagnostic accuracy of IR events, and their concordance with corresponding CEC-adjudicated events. Methods: We report the proportion of myocardial infarction, bleeding, stroke, and stent thrombosis triggers with sufficient evidence for assessment (feasibility) that were adjudicated as outcome events (efficiency), stratified by source (IR or non-IR). Using CEC-adjudicated events as criterion standard, we describe sensitivity, specificity, positive and negative predictive value, and global diagnostic accuracy of IR events. Using Gwet AC coefficient, we examine the concordance between IR- and corresponding CEC-adjudicated triggers. There was sufficient evidence for assessment for 2592 (98.3%) of 2636 triggers. Results: Overall, the adjudicated end point-to-trigger ratio was high and similar between IR- (88%) and non-IR–reported (87%) triggers. The global diagnostic accuracy and concordance between IR-reported and CEC-adjudicated outcome events was 0.70 (95% CI, 0.65–0.74) and 0.54 (95% CI, 0.45–0.62), respectively, for myocardial infarction; 0.77 (95% CI, 0.75–0.79) and 0.71 (95% CI, 0.68–0.74) for bleeding; 0.70 (95% CI, 0.62–0.79) and 0.59 (95% CI, 0.43–0.74) for stroke; 0.59 (95% CI, 0.52–0.66) and 0.39 (95% CI, 0.25–0.53) for stent thrombosis. For IR bleedings, the concordance with the CEC on type of events was generally weak. Conclusions: Implementing CEC adjudication in a pragmatic open-label trial with IR events is feasible and efficient. Our findings of modest global diagnostic accuracy for IR events and generally weak concordance between investigators and CEC support the role for CEC adjudication in such settings. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03231059.
- 1 February 2021
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 14 (2) , 144-151
Comparison of Investigator-Reported and Clinical Event Committee–Adjudicated Outcome Events in GLASSY
Background: Event adjudication by a clinical event committee (CEC) provides a standardized, independent outcome assessment. However, the added value of CEC to investigators reporting remains debated. GLASSY (GLOBAL LEADERS Adjudication Sub-Study) implemented, in a subset of the open-label, investigator-reported (IR) GLOBAL LEADERS trial, an independent adjudication process of reported and unreported potential outcome events (triggers). We describe metrics of GLASSY feasibility and efficiency, diagnostic accuracy of IR events, and their concordance with corresponding CEC-adjudicated events. Methods: We report the proportion of myocardial infarction, bleeding, stroke, and stent thrombosis triggers with sufficient evidence for assessment (feasibility) that were adjudicated as outcome events (efficiency), stratified by source (IR or non-IR). Using CEC-adjudicated events as criterion standard, we describe sensitivity, specificity, positive and negative predictive value, and global diagnostic accuracy of IR events. Using Gwet AC coefficient, we examine the concordance between IR- and corresponding CEC-adjudicated triggers. There was sufficient evidence for assessment for 2592 (98.3%) of 2636 triggers. Results: Overall, the adjudicated end point-to-trigger ratio was high and similar between IR- (88%) and non-IR–reported (87%) triggers. The global diagnostic accuracy and concordance between IR-reported and CEC-adjudicated outcome events was 0.70 (95% CI, 0.65–0.74) and 0.54 (95% CI, 0.45–0.62), respectively, for myocardial infarction; 0.77 (95% CI, 0.75–0.79) and 0.71 (95% CI, 0.68–0.74) for bleeding; 0.70 (95% CI, 0.62–0.79) and 0.59 (95% CI, 0.43–0.74) for stroke; 0.59 (95% CI, 0.52–0.66) and 0.39 (95% CI, 0.25–0.53) for stent thrombosis. For IR bleedings, the concordance with the CEC on type of events was generally weak. Conclusions: Implementing CEC adjudication in a pragmatic open-label trial with IR events is feasible and efficient. Our findings of modest global diagnostic accuracy for IR events and generally weak concordance between investigators and CEC support the role for CEC adjudication in such settings. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03231059.
- Open Access
- 1 April 2018
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 13 (17) , 2026-2035
First-in-man randomised comparison of the BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: the PIONEER trial
A second iteration of a sirolimus-eluting stent (SES) that has a biodegradable PLGA polymer coating with an electrografting base layer on a thin-strut (80 µm) cobalt-chromium platform (BuMA Supreme; SINOMED, Tianjin, China) has been developed. This first-in-man trial aimed to assess the efficacy and safety of the novel device. This randomised, multicentre, single-blinded, non-inferiority trial compared the BuMA Supreme SES versus a contemporary durable polymer zotarolimus-eluting stent (ZES) in terms of angiographic in-stent late lumen loss (LLL) at nine-month follow-up as the primary endpoint. A total of 170 patients were randomly allocated to treatment with either SES (n=83) or ZES (n=87). At nine-month angiographic follow-up, in-stent LLL was 0.29±0.33 mm in the SES group and 0.14±0.37 mm in the ZES group (pnon-inferiority=0.45). The in-stent percent diameter stenosis and the binary restenosis rate of the two treatment arms were similar (19.2±12.0% vs. 16.1±12.6%, p=0.09, and 3.3% vs. 4.4%, p=1.00, respectively). At 12-month clinical follow-up, there was no difference between treatment arms with regard to the device-oriented composite clinical endpoint (4.9% vs. 5.7%; p=0.72). The PIONEER trial did not meet its primary endpoint in terms of in-stent LLL at nine-month follow-up. However, this result did not translate into any increase in restenosis rate or impairment in 12-month clinical outcomes.
- 1 April 2018
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 13 (17) , 2026-2035
Open AccessFirst-in-man randomised comparison of the BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: the PIONEER trial
A second iteration of a sirolimus-eluting stent (SES) that has a biodegradable PLGA polymer coating with an electrografting base layer on a thin-strut (80 µm) cobalt-chromium platform (BuMA Supreme; SINOMED, Tianjin, China) has been developed. This first-in-man trial aimed to assess the efficacy and safety of the novel device. This randomised, multicentre, single-blinded, non-inferiority trial compared the BuMA Supreme SES versus a contemporary durable polymer zotarolimus-eluting stent (ZES) in terms of angiographic in-stent late lumen loss (LLL) at nine-month follow-up as the primary endpoint. A total of 170 patients were randomly allocated to treatment with either SES (n=83) or ZES (n=87). At nine-month angiographic follow-up, in-stent LLL was 0.29±0.33 mm in the SES group and 0.14±0.37 mm in the ZES group (pnon-inferiority=0.45). The in-stent percent diameter stenosis and the binary restenosis rate of the two treatment arms were similar (19.2±12.0% vs. 16.1±12.6%, p=0.09, and 3.3% vs. 4.4%, p=1.00, respectively). At 12-month clinical follow-up, there was no difference between treatment arms with regard to the device-oriented composite clinical endpoint (4.9% vs. 5.7%; p=0.72). The PIONEER trial did not meet its primary endpoint in terms of in-stent LLL at nine-month follow-up. However, this result did not translate into any increase in restenosis rate or impairment in 12-month clinical outcomes.
- Open Access
- 1 February 2016
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 11 (11) , e1267-e1274
STENTYS Self-Apposing® sirolimus-eluting stent in ST-segment elevation myocardial infarction: results from the randomised APPOSITION IV trial
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 1 February 2016
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 11 (11) , e1267-e1274
Open AccessSTENTYS Self-Apposing® sirolimus-eluting stent in ST-segment elevation myocardial infarction: results from the randomised APPOSITION IV trial
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- Open Access
- 1 February 2013
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 68 (1) , 1-9
Long-term follow-up after percutaneous coronary intervention with polytetrafl uoroethylene-covered Symbiot™ stents compared to bare metal stents, with and without FilterWire™ embolic protection, in diseased saphenous vein grafts
The long-term clinical outcome of covered stents in the percutaneous treatment of diseased saphenous vein graft (SVG) has been disappointing. The single self-expanding polytetrafluoroethylene (PTFE)-covered Symbiot stent with a unique profile may present advantages that translate into superior long-term clinical outcomes. This study evaluated the safety, effectiveness and clinical outcome of the Symbiot covered stent system (Boston Scientific, Natick, Mass.) and FilterWire EX (Boston Scientific, Natick, Mass.) versus bare metal stents (BMS) in SVG intervention. Between January 2003 and August 2005, 90 patients with degenerative SVG lesions were prospectively randomized at 6 study sites to Symbiot implantation (n = 30), BMS with FilterWire as embolic protection device (EPD, n = 30), or BMS without EPD (control group, n = 30). The primary end point was reduction in peri-procedural cardiac enzyme rise. The major secondary end points were in-hospital, 6-month and long-term target vessel failure rates, defined as the cumulative of death, myocardial infarction and clinically driven target lesion revascularization. There was no significant reduction in median [IQR] post-procedural troponin-I rise in the Symbiot group compared to the FilterWire or the control group (0.08 [0-1.40] microg/l; 0.06 [0-0.28] microg/l; and 0.04 [0-0.31] microg/l, P = 0.58). At 7.4 +/- 1.3 (mean +/- SD) years, there were numerically less deaths in the Symbiot group, although this did not reach statistical significance (P = 0.20). There was no significant difference in TVF-free survival between the treatment groups (P = 0.98). This study failed to show a procedural or long-term clinical advantage for the Symbiot PTFE-covered stent in the treatment of degenerated SVG.
- 1 February 2013
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 68 (1) , 1-9
Open AccessLong-term follow-up after percutaneous coronary intervention with polytetrafl uoroethylene-covered Symbiot™ stents compared to bare metal stents, with and without FilterWire™ embolic protection, in diseased saphenous vein grafts
The long-term clinical outcome of covered stents in the percutaneous treatment of diseased saphenous vein graft (SVG) has been disappointing. The single self-expanding polytetrafluoroethylene (PTFE)-covered Symbiot stent with a unique profile may present advantages that translate into superior long-term clinical outcomes. This study evaluated the safety, effectiveness and clinical outcome of the Symbiot covered stent system (Boston Scientific, Natick, Mass.) and FilterWire EX (Boston Scientific, Natick, Mass.) versus bare metal stents (BMS) in SVG intervention. Between January 2003 and August 2005, 90 patients with degenerative SVG lesions were prospectively randomized at 6 study sites to Symbiot implantation (n = 30), BMS with FilterWire as embolic protection device (EPD, n = 30), or BMS without EPD (control group, n = 30). The primary end point was reduction in peri-procedural cardiac enzyme rise. The major secondary end points were in-hospital, 6-month and long-term target vessel failure rates, defined as the cumulative of death, myocardial infarction and clinically driven target lesion revascularization. There was no significant reduction in median [IQR] post-procedural troponin-I rise in the Symbiot group compared to the FilterWire or the control group (0.08 [0-1.40] microg/l; 0.06 [0-0.28] microg/l; and 0.04 [0-0.31] microg/l, P = 0.58). At 7.4 +/- 1.3 (mean +/- SD) years, there were numerically less deaths in the Symbiot group, although this did not reach statistical significance (P = 0.20). There was no significant difference in TVF-free survival between the treatment groups (P = 0.98). This study failed to show a procedural or long-term clinical advantage for the Symbiot PTFE-covered stent in the treatment of degenerated SVG.